Chest
Selected ReportsDiffuse Alveolar Hemorrhage Induced by Everolimus
Section snippets
Discussion
Everolimus is a recently developed proliferation signal inhibitor (PSI) or mammalian target of rapamycin inhibitor, with a molecular structure very similar to that of sirolimus. It is mainly used as an immunosuppressive agent following organ transplantation, but has also been investigated as an antineoplastic agent and as adjunctive therapy in systemic diseases.1 PSIs have antiangiogenic and antiproliferative effects by inhibiting cellular proliferation of both hematopoietic and
Acknowledgments
Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
References (7)
- et al.
Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy
Transplant Proc
(2007) - et al.
Resolution of sirolimus-induced pneumonitis after conversion to everolimus
Transplant Proc
(2006) - et al.
Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient—not all proliferation signal inhibitors are the same: a case report
Transplant Proc
(2007)
Cited by (0)
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml).